Atosiban EVER Pharma

Hormone Therapeutic
3 Strengths – 6,75 mg/0,9 ml; 37,5 mg/5 ml; 75 mg/10 ml

Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labour.

Atosiban EVER is indicated to delay imminent pre-term birth in pregnant adult women with a gestational age from 24 until 33 completed weeks.

Available as a convenient ready to use fixed dose (bolus injection) and fixed volumes concentrate for dilution (high dose/low dose infusions).

Learn more: www.evervalinject.com

Cabazitaxel EVER Pharma

Oncology
3 Strengths – 45 mg/4,5 ml; 50 mg/5 ml; 60 mg/6 ml

Cabazitaxel is a third-generation antineoplastic taxane and was the first therapy to show a survival benefit for the treatment of patients with docetaxel-refractory mCRPC.

Cabazitaxel EVER Pharma is provided as a single vial, ready to dilute formulation and is available in vial sizes covering the common range of patient specific doses for economy and convenience.

Learn more: www.evervalinject.com

Cebrium®

Nutritional supplement

Cebrium® capsules are clinically tested nutritional supplements for light, age-related memory problems and contain 90 mg of N-Pep-12® that should be administered once per day.

Find out more: info@memomind.com

Cerebrolysin®

Neurology
7 Strengths

Cerebrolysin® is a biotechnologically prepared peptide that stimulates neurotrophic regulation in the central nervous system.

Cerebrolysin® is used worldwide for treatment of ischemic and hemorrhagic stroke, traumatic brain injuries, different forms of dementia (vascular dementia, Alzheimer’s disease), cognitive disorders and for the prevention of cognitive decline after brain injuries.

Patients with either acute or degenerative neurological diseases benefit from the neuro-protective and neuro-regenerative properties of Cerebrolysin®.

The recommended dosage range of Cerebrolysin® is between 10 and 50 ml per day. It is recommended that the administration is done by infusion with an infusion duration of 15 minutes. For lower doses, Cerebrolysin® can be injected intramuscularly for doses of up to 5 ml and intravenously for doses up to 10 ml, in both cases without dilution.

Learn more: www.cerebrolysin.com

Dacepton®

Neurology
2 Strengths – 5 mg/ml; 10 mg/ml   

Dacepton® (Apomorphine hydrochloride) is used for treatment of movement disorders (“on-off” phenomena) in patients with Parkinson’s disease and who cannot be effectively treated using oral anti-Parkinson medicine1.

Apomorphine is the strongest clinically available dopamine agonist and belongs to the pharmacological class of anti-Parkinson medicine. The effect of apomorphine unfolds through direct stimulation of dopamine receptors in the central nervous system. A rapid onset action of apomorphine is achieved through subcutaneous administration.

Learn more: www.dacepton.com

Sources

1 SmPC in current version

Dexmedetomidine EVER Pharma

Anesthetic
3 Strengths – 200 mcg/2 ml; 400 mcg/4 ml; 1,000 mcg/10 ml

Dexmedetomidine is a selective α2-adrenoceptor agonist developed for use as an anesthetic providing light to moderate sedation.

Dexmedetomidine EVER was the first dexmedetomidine product in Europe indicated for both Adult Procedural  and Sedation1 of Adult ICU Patients2,3. The inclusion of Adult Procedural Sedation to the label now provides the clinician with greater choice when selecting the appropriate sedative for adult patients undergoing diagnostic or surgical procedures.

All fill sizes now available as either ampoules or vials: 200µg/2ml, 400µg/4ml, 1000µg/10ml

Learn more: www.evervalinject.com

Sources

1 Sedation of non-intubated adult patients prior to and /or during diagnostic or surgical procedures requiring sedation (i.e.) procedural/awake sedation

2 Use of the product in the Adult ICU setting is limited to certain EU countries only at this time: Germany, Austria, UK, Poland, Netherlands, Czech Republic and Ireland. Please refer to individual country SmPC.

3 Sedation of adult ICU patients requiring sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation Scale (RASS) 0 to -3)

Docetaxel EVER Valinject

Oncology
3 Strenghts – 20 mg/1 ml; 80 mg/4 ml; 160 mg/8 ml

Docetaxel EVER Valinject for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, adenocarcinoma of the stomach, and head and neck cancer. Docetaxel is given as a one-hour infusion every 3 weeks.

Learn more: www.evervalinject.com

Fulvestrant EVER Pharma

Oncology
1 Strength – 250 mg/5 ml

The first Fulvestrant in Europe approved for storage at room temperature.

Fulvestrant EVER Pharma is indicated as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:

  • Not previously treated with endocrine therapy
  • Or with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy.

Fulvestrant EVER is also indicated in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.

Learn more: www.evervalinject.com

MemoProve®

Nutritional supplement

MemoProve® tablets are clinically tested nutritional supplements for light, age-related memory problems and contain 90 mg of N-Pep-12® that should be administered once per day.

Find out more: info@memomind.com

Oxytocin EVER Pharma

Hormone Therapeutic
2 Strenghts – 5 IU/1 ml; 10 IU/1 ml

Oxytocin is a drug that belongs to the group of medicines called oxytocins and it is identical with oxytocin, a hormone released by the pituitary gland, which has an effect on the muscles of the uterus (womb).

Oxytocin EVER Pharma is a generic version of Syntocinon® (Novartis) and indicated for the induction of labour for medical reasons; stimulation of labour in hypotonic uterine inertia; during caesarean section, following delivery of the child; prevention and treatment of postpartum uterine atony and haemorrhage. Early stages of pregnancy as an adjunctive therapy for the management of incomplete, inevitable, or missed abortion.

Learn more: www.evervalinject.com

Paclitaxel EVER Pharma

Oncology
3 Strenghts – 30 mg/5 ml; 100 mg/16.7 ml; 300 mg/50 ml

Paclitaxel EVER Pharma is indicated for the treatment of ovarian carcinoma, breast carcinoma, advanced non-clinical bronchial carcinoma and AIDS-associated Kaposi sarcoma.

Learn more: www.evervalinject.com

Pemetrexed EVER Valinject

Oncology
3 Strenghts – 100 mg/4 ml; 500 mg/20 ml; 1000 mg/40 ml

Pemetrexed is an antineoplastic chemotherapy drug. It is used in the treatment of malignant mesothelioma and locally advanced or metastatic nonsquamous non-small cell lung cancer.

Pemetrexed EVER Pharma is provided as a ready to dilute liquid formulation that can be stored at room temperature and is available in 3 vial sizes for economy and convenience.

Learn more: www.evervalinject.com

Tachyben®

Cardiovascular disease
3 Strenghts – 25 mg; 50 mg; 100 mg

Tachyben® is used for intravenous treatment of hypertensive emergencies (e.g. critical rise in blood pressure), in cases of severe and very severe forms of hypertensive disease as well as in cases of hypertension resistant to treatment.

It is used to control lowering of blood pressure in hypertensive patients during and/or after surgery.1

Learn more: www.tachyben.com

Sources

1 SmPC in current version

Terlipressin EVER Pharma

Gastroenterology
2 Strengths – 1 mg/5 ml; 2 mg/10 ml

Terlipressin EVER Pharma is indicated for the treatment of bleeding oesophageal varices and Hepato-renal syndrome type 1.

NICE (UK) guidelines are to offer terlipressin to patients with suspected variceal bleeding at presentation and the WGO recommend it as the first choice for pharmacological therapy to control bleeding and mortality.

Learn more: www.evervalinject.com